keyword
MENU ▼
Read by QxMD icon Read
search

Radium-223

keyword
https://www.readbyqxmd.com/read/29905090/narrative-medicine-in-metastatic-prostate-cancer-reveals-ways-to-improve-patient-awareness-quality-of-care
#1
Giuseppe De Vincentis, Fabio Monari, Sergio Baldari, Matteo Salgarello, Viviana Frantellizzi, Elisabetta Salvi, Luigi Reale, Silvia Napolitano, Giario Conti, Enrico Cortesi
AIM: To describe the journey of patients with metastatic castration-resistant prostate cancer (mCRPC) in treatment with radium-223. METHODS: A multiperspective analysis was performed using narrative medicine in four Italian centers. RESULTS: The substantial impact of mCRPC on quality of life through all phases of the disease was described. After an initial lack of awareness of the disease or denial of its effects, symptoms of pain, fatigue and side effects often led to sadness, fear and loneliness...
June 15, 2018: Future Oncology
https://www.readbyqxmd.com/read/29888184/18-fluoride-labeled-sodium-fluoride-positron-emission-tomography-is-effective-for-assessing-the-therapeutic-effect-of-radium-223-a-case-report
#2
Kousuke Hamada, Satoshi Tamada, Taro Iguchi, Minoru Kato, Shigeaki Higashiyama, Joji Kawabe, Tatsuya Nakatani
No abstract text is available yet for this article.
July 2018: Urology Case Reports
https://www.readbyqxmd.com/read/29882332/treatment-selection-for-men-with-metastatic-prostate-cancer-who-progress-on-upfront-chemo-hormonal-therapy
#3
Pedro Barata, Hamid Emamekhoo, Prateek Mendiratta, Vadim Koshkin, Allison Tyler, Moshe Ornstein, Brian I Rini, Timothy Gilligan, Christos Kyriakopoulos, Jorge A Gracia
BACKGROUND: Androgen deprivation therapy plus docetaxel (D-ADT) increases overall survival (OS) in men with high-volume, metastatic hormone-sensitive prostate cancer (mHSPC). Although the vast majority of men initially respond to D-ADT, most will progress and develop castration-resistant prostate cancer (CRPC). Little is known about the optimal treatment sequence for men with progressive disease on D-ADT. PATIENT AND METHODS: Retrospective analysis of consecutive mHSPC patients treated with ≥3 cycles of D-ADT at Cleveland Clinic and University of Wisconsin-Madison was undertaken...
June 7, 2018: Prostate
https://www.readbyqxmd.com/read/29861164/osteonecrosis-of-the-jaw-in-a-patient-with-bone-metastatic-prostate-cancer-after-long-term-bisphosphonate-treatment-with-severe-deterioration-following-radium-223
#4
Bente Brokstad Herlofson, Gry Karina Kjølle, Kristine Løken Westgaard, Ayca M Lønndalen, Øyvind S Bruland
No abstract text is available yet for this article.
May 16, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29859504/targeted-alpha-therapy-using-radium-223-from-physics-to-biological-effects
#5
REVIEW
I A Marques, A R Neves, A M Abrantes, A S Pires, E Tavares-da-Silva, A Figueiredo, M F Botelho
With the advance of the use of ionizing radiation in therapy, targeted alpha therapy (TAT) has assumed an important role around the world. This kind of therapy can potentially reduce side effects caused by radiation in normal tissues and increased destructive radiobiological effects in tumor cells. However, in many countries, the use of this therapy is still in a pioneering phase. Radium-223 (223 Ra), an alpha-emitting radionuclide, has been the first of its kind to be approved for the treatment of bone metastasis in metastatic castration-resistant prostate cancer...
May 25, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29848570/radium-223-dichloride-in-combination-with-vascular-endothelial-growth-factor-targeting-therapy-in-advanced-renal-cell-carcinoma-with-bone-metastases
#6
Rana R McKay, Dominick Bossé, Kathryn P Gray, M Dror Michaelson, Katherine M Krajewski, Heather A Jacene, Meghara Meghara Walsh, Joaquim Bellmunt, Mark Pomerantz, Lauren C Harshman, Toni K Choueiri
PURPOSE: This study investigates the biologic activity of radium-223 with vascular endothelial growth factor (VEGF)-targeted therapy in patients with advanced renal cell carcinoma (aRCC) and bone metastases. EXPERIMENTAL DESIGN: Fifteen treatment-naïve patients (n=15) received pazopanib 800 mg orally once-daily and 15 previously-treated patients received sorafenib 400 mg orally twice-daily. Radium-223 55 kilobecquerel/kg was administered concurrently every four weeks for up to 6 infusions in both cohorts...
May 30, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29800797/the-impact-of-age-on-radium-223-distribution-and-an-evaluation-of-molecular-imaging-surrogates
#7
Wen Jiang, David Ulmert, Brian W Simons, Diane S Abou, Daniel L J Thorek
INTRODUCTION: Radium-223 dichloride is the first alpha-particle emitting therapeutic agent approved by FDA and EMA for bone metastatic castration-resistant prostate cancer. We studied its age-dependent biodistribution in mice, and compared it with [99m Tc]Tc-MDP and [18 F]NaF aiming to identify a potential imaging surrogate to predict [223 Ra]RaCl2 whole-body localization. METHODS: Male C57Bl/6 mice dosed with [223 Ra]RaCl2 were sacrificed at different time points to explore [223 Ra]RaCl2 whole-body distribution...
May 8, 2018: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29790867/fluorine-18-fluorocholine-pet-ct-parameters-predictive-for-hematological-toxicity-to-radium-223-therapy-in-castrate-resistant-prostate-cancer-patients-with-bone-metastases-a-pilot-study
#8
Lavinia Vija Racaru, Mathieu Sinigaglia, Salim Kanoun, Fayçal Ben Bouallègue, Ilan Tal, Sévérine Brillouet, Mathilde Bauriaud-Mallet, Slimane Zerdoud, Lawrence Dierickx, Delphine Vallot, Olivier Caselles, Erwan Gabiache, Pierre Pascal, Frederic Courbon
PURPOSE: This study aims to predict hematological toxicity induced by Ra therapy. We investigated the value of metabolically active bone tumor volume (MBTV) and total bone lesion activity (TLA) calculated on pretreatment fluorine-18-fluorocholine (F-FCH) PET/CT in castrate-resistant prostate cancer (CRPC) patients with bone metastases treated with Ra radionuclide therapy. PATIENTS AND METHODS: F-FCH PET/CT imaging was performed in 15 patients with CRPC before treatment with Ra...
May 21, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29787892/the-role-of-bisphosphonates-or-denosumab-in-light-of-the-availability-of-new-therapies-for-prostate-cancer
#9
REVIEW
Fred Saad, Cora N Sternberg, Peter F A Mulders, Daniela Niepel, Bertrand F Tombal
Most men with advanced prostate cancer will develop bone metastases, which have a substantial impact on quality of life. Bone metastases can lead to skeletal-related events (SREs), which place a burden on patients and healthcare systems. For men with castration-resistant prostate cancer (CRPC) and bone metastases, the treatment landscape has evolved rapidly over the past few years. The relatively recent approvals of the hormonal agents abiraterone acetate and enzalutamide, second-line chemotherapy cabazitaxel, and the radiopharmaceutical radium-223 dichloride (radium-223), have provided clinicians with a greater choice of treatments...
May 3, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29785515/prostate-specific-antigen-flare-induced-by-223-racl-2-in-patients-with-metastatic-castration-resistant-prostate-cancer
#10
Angelo Castello, H A Macapinlac, E Lopci, E B Santos
PURPOSE: Prostate-specific antigen (PSA) flare is a well-known phenomenon in patients with prostate cancer, but its impact during radium-223 dichloride (223 RaCl2 ) therapy is still unclear. This radioisotope has shown to improve overall survival in metastatic castration-resistant prostate cancer (mCRPC). We sought to evaluate the impact of PSA flare on survival and its relation with metabolic parameters on 18 F-labeled sodium fluoride PET/CT. METHODS: We conducted a retrospective study of 168 patients with mCRPC (median age 69; median PSA 29...
May 21, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29780751/metastatic-castration-resistant-prostate-cancer-and-the-challenge-of-a-patient-with-chronic-kidney-disease-in-hemodialysis
#11
Joana Simões, Isabel Augusto, Sara Meireles, Lurdes Vendeira, Carlos Silva
At a time when the population shows increasing longevity, entities such as cancer and chronic kidney disease (CKD) are more frequently connected. In the United States, approximately 6% of the patients on hemodialysis have cancer. The challenge to manage oncologic patients with CKD in a hemodialytic program represents a great shortage of available information on the choice of the best drug, timing, dosage adjustments, dialysis method, and treatment safety. We present the case of a patient with prostate cancer and terminal CKD in hemodialysis, and the treatment sequence after the development of resistance to hormonal blockade therapy, which included docetaxel, enzalutamide, and radium-223...
April 2018: Autopsy & Case Reports
https://www.readbyqxmd.com/read/29778323/is-there-a-flare-phenomenon-on-bone-scintigraphy-in-men-with-advanced-prostate-cancer-treated-with-radium-223
#12
Gesa Isensee, Anne Péporté, Joachim Müller, Sabine Schmid, Silke Gillessen, Aurelius Omlin
INTRODUCTION: Radium-223 is an approved survival-prolonging treatment option in men with castration-resistant prostate cancer (mCRPC) and bone metastases. In the registration trial (ALSYMPCA), no regular imaging was mandated. We aimed to analyze men with metastatic mCRPC treated with radium-223 who had bone scintigraphy for staging and treatment monitoring. PATIENTS AND METHODS: Retrospective chart review was performed of mCRPC patients who received 6 cycles of radium-223 and who underwent bone scintigraphy before start of radium-223 and after 3 and 6 cycles of treatment...
April 23, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29734647/recent-advances-in-prostate-cancer-treatment-and-drug-discovery
#13
REVIEW
Ekaterina Nevedomskaya, Simon J Baumgart, Bernard Haendler
Novel drugs, drug sequences and combinations have improved the outcome of prostate cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and apalutamide which target androgen receptor (AR) signaling, radium-223 dichloride for reduction of bone metastases, sipuleucel-T immunotherapy and taxane-based chemotherapy. Adding abiraterone acetate to androgen deprivation therapy (ADT) in order to achieve complete androgen blockade has proven highly beneficial for treatment of locally advanced prostate cancer and metastatic hormone-sensitive prostate cancer (mHSPC)...
May 4, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29719487/ra223-in-bone-metastases-with-osteolytic-activity
#14
Renato Patrizio Costa, Davide Cardile, Alessandra Murabito, Vincenzo Tripoli, Francesco Verderame
Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In our institution, a patient with breast cancer affected by osteolytic metastases was treated with off-label use of Ra223. The evaluation of the deposit areas of Ra223 showed a perfect overlap with the regions of osteolysis previously detected by scintigraphy, indicating a possible therapeutic effect...
April 2018: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29714668/-223-ra-chloride-therapy-in-men-with-hormone-refractory-prostate-cancer-and-skeletal-metastases-real-world-experience
#15
Giuseppe Boni, Sara Mazzarri, Claudia Cianci, Luca Galli, Azzurra Farnesi, Eugenio Borsatti, Roberto Bortolus, Lucia Fratino, Carlo Gobitti, Elda Lamaj, Pietro Ghedini, Elisa Lodi Rizzini, Francesco Massari, Valeria Dionisi, Stefano Fanti, Duccio Volterrani, Fabio Monari
BACKGROUND: Radium-223 (223 Ra) chloride, an alpha emitter, has been shown to improve overall survival (OS) and pain control, and to delay skeletal-related events, in patients with castration-resistant prostate cancer (CRPC) and bone metastases. Our retrospective observational study presents the first Italian experience on the efficacy and safety of 223 Ra therapy in routine clinical practice. METHODS: A total of 83 patients with metastatic CRPC were treated with 223 Ra at 3 Italian centers between August 2013 and August 2016...
April 1, 2018: Tumori
https://www.readbyqxmd.com/read/29688882/disparity-in-public-funding-of-therapies-for-metastatic-castrate-resistant-prostate-cancer-across-canadian-provinces
#16
Dixon T S Woon, Thenappan Chandrasekar, Lorne Aaron, Naveen S Basappa, Kim N Chi, Henry J Conter, Brita Danielson, Sebastien J Hotte, Shawn Malone, Fred Saad, Bobby Shayegan, Laura Park-Wyllie, Robert J Hamilton
INTRODUCTION: Treatment using abiraterone acetate, enzalutamide, cabazitaxel, and radium-223 (Ra-223) improve overall survival (OS) and quality of life for patients with metastatic castrate-resistant prostate cancer (mCRPC). Despite their proven benefits, access to these therapies is not equal across Canada. METHODS: We describe provincial differences in access to approved mCRPC therapies. Data sources include the pan-Canadian Oncology Drug Review database, provincial cancer care resources, and correspondence with pharmaceutical companies...
April 12, 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29678471/hematologic-toxicity-from-radium-223-therapy-for-bone-metastases-in-castration-resistant-prostate-cancer-risk-factors-and-practical-considerations
#17
REVIEW
Heather Jacene, Leonard Gomella, Evan Y Yu, Eric M Rohren
Radium-223 dichloride is an α-emitting radiopharmaceutical that localizes to bone matrix and is approved for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. The cumulative impact of Ra-223 and other therapeutic agents for metastatic CRPC on myelosuppression in bone marrow is unknown. The phase 3 randomized, double-blind, placebo-controlled ALSYMPCA trial of Ra-223 in patients with CRPC and symptomatic bone metastases demonstrated a significant improvement in overall survival...
March 23, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29673712/update-on-systemic-prostate-cancer-therapies-management-of-metastatic-castration-resistant-prostate-cancer-in-the-era-of-precision-oncology
#18
REVIEW
Philipp Nuhn, Johann S De Bono, Karim Fizazi, Stephen J Freedland, Maurizio Grilli, Philip W Kantoff, Guru Sonpavde, Cora N Sternberg, Srinivasan Yegnasubramanian, Emmanuel S Antonarakis
CONTEXT: Introduction of novel agents for the management of advanced prostate cancer provides a range of treatment options with notable benefits for men with metastatic castration-resistant prostate cancer (mCRPC). At the same time, understanding of optimal patient selection, effective sequential use, and development of resistance patterns remains incomplete. OBJECTIVE: To review current systemic therapies and recent advances in drug development for mCRPC and strategies to aid in patient selection and optimal sequencing...
April 16, 2018: European Urology
https://www.readbyqxmd.com/read/29662636/analysis-of-hematological-parameters-as-prognostic-markers-for-toxicity-and-survival-of-223-radium-treatment
#19
Asha Leisser, Marzieh Nejabat, Markus Hartenbach, Reza Agha Mohammadi Sareshgi, Shahrokh Shariat, Gero Kramer, Michael Krainer, Marcus Hacker, Alexander R Haug
223 Radium (223 Ra) has emerged as treatment prolonging survival in patients with metastatic castration-resistant prostate cancer (CRPC). As 223 Ra can cause hematotoxicity (HT), pre-existing hematopoiesis might influence the efficacy of 223 Ra and the rate of hematotoxicity, but as to our knowledge such data has not been published yet, we retrospectively conducted an analysis on patients receiving 223 Ra. 54 patients treated with 223 Ra had a median survival of 67 weeks, which was significantly reduced in patients with pre-existing Hb toxicity (Tox) grade 2 (48 weeks P = 0...
March 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29661653/radium-223-in-the-treatment-of-bone-metastasis-in-patients-with-castration-resistant-prostate-cancer-review-and-procedure
#20
J Orcajo-Rincon, A P Caresia-Aróztegui, M Del Puig Cózar-Santiago, J R García-Garzón, M de Arcocha-Torres, R C Delgado-Bolton, M J García-Velloso, S Alvarez-Ruiz, A M García-Vicente
Bone metastatic disease is the main cause of morbidity / mortality in patients with prostate cancer, presenting frequently as bone pain, pathological fractures or spinal cord compression, which requires early and timely therapy. Although, for the moment, the therapeutic window for its use has not been definitively established, radium-223 (223 Ra), an alpha particle emitter, has proved to be an effective therapeutic tool, pre or post-chemotherapy, in patients with castration-resistant prostate cancer with symptomatic bone metastases and absence of visceral metastases, significantly modifying the prognosis of the disease...
April 13, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
keyword
keyword
25667
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"